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Pentacyclic triterpenes are natural compounds with a large plethora of described 
pharmacotherapeutic effects. Betulinic acid (BA) stands as a widely studied compound of this 
class, exhibiting multiple therapeutic effects such as: antiinflammatory, antiviral and 
antiproliferative. The low bioavailability o BA represents a major drawback which represented 
a starting point of multiple research directions, having the sole purpose of increasing BA’s 
bioavailability. One direction employed by the literature in this regard represents the 
synthesis of cyclodextrin (CD) inclusion complexes (1). Knowing that BA is a large pentacyclic 
structure herein we propose the synthesis of a BA-1,2,4-triazole derivative that can be easily 
incorporated into CD and can exhibit an improved antiproliferative effect as compared to BA. 
The proposed derivatization requires obtaining a BA halogenated derivative by allylic 
bromuration (C-30), that ca be subsequently used as an alkylating agent against a 3-thiol-1,2,4-
triazole derivative. 30-bromo-BA was obtained according to previously reported methods 
using NBS (2). The obtained compound was purified by flash column chromatography. The BA 
derivative was later reacted to 5-(4-metoxifenil)-4H-1,2,4-triazol-3-thiol, in presence of EtOH 
and EtONa. The completion of the reaction was monitored by TLC. The obtained compound 
was purified by flash column chromatography. FT-IR and LC-MS analysis confirmed the 
formation of 30-[3-(4-metoxiphenyl)-1H-1,2,4-triazol-5-yl-sulfanyl]-betulinic acid. Docking 
studies of the BA derivative an BA using CD as targets revealed that indeed our obtained 
compound shows a theoretical stronger affinity towards CD as compared to BA. The obtained 
compound and its CD formulations will be subjected to further biological assessments. 
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